← Eichor
Study identifier: NCT07441694 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Condition: Myeloproliferative Neoplasms  ·  Sponsor: Incyte Corporation

PhasePhase 1
Planned participants218
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Incyte Corporation Call Center (US)  ·  1.855.463.3463  ·  medinfo@incyte.com

Incyte Corporation Call Center (ex-US)  ·  +800 00027423  ·  eumedinfo@incyte.com

Always discuss trial participation with your own doctor first.

Locations (54)

University of Alabama At BirminghamBirmingham, Alabama, United StatesNot Yet Recruiting
City of Hope-Lennar Foundation Cancer CenterIrvine, California, United StatesNot Yet Recruiting
Usc Norris Comprehensive Cancer CenterLos Angeles, California, United StatesNot Yet Recruiting
UCLA Medical Hematology & OncologyLos Angeles, California, United StatesNot Yet Recruiting
Yale Cancer CenterNew Haven, Connecticut, United StatesNot Yet Recruiting
University of MiamiMiami, Florida, United StatesNot Yet Recruiting
Moffitt Cancer CenterTampa, Florida, United StatesNot Yet Recruiting
Winship Cancer Institute of Emory UniversityAtlanta, Georgia, United StatesRecruiting
John Hopkins HospitalBaltimore, Maryland, United StatesNot Yet Recruiting
Massachusetts General HospitalBoston, Massachusetts, United StatesNot Yet Recruiting
Washington University School of MedicineSt Louis, Missouri, United StatesNot Yet Recruiting
Memorial Sloan Kettering Cancer CenterNew York, New York, United StatesNot Yet Recruiting

+ 42 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07441694